再生元製藥 (Chinese Wikipedia)
Analysis of information sources in references of the Wikipedia article "再生元製藥" in Chinese language version.
refsWebsite
Global rank
Chinese rank
1st place
1st place
433rd place
602nd place
54th place
88th place
7th place
31st place
406th place
918th place
low place
low place
fda.gov
- Archived copy. [2015-07-29]. （原始内容存档于2015-07-27）.
- FDA approves first treatment for advanced form of the second most common skin cancer (NASDAQ:REGN). fda.gov/NewsEvents. [2019-01-11]. （原始内容存档于2019-04-23）.
forbes.com
- Herper, Matthew. How Two Guys From Queens Are Changing Drug Discovery. Forbes (United States). August 14, 2013 [March 22, 2014]. （原始内容存档于2014-03-16）.
fortune.com
- Regeneron Pharmaceuticals. Fortune. [2018-12-31]. （原始内容存档于2019-06-09）.
nytimes.com
- Regulators Approve a Drug for an Eye Condition. The New York Times. Associated Press. November 18, 2011 [2019-01-11]. （原始内容存档于2019-06-05）.
prnewswire.com
- Inc., Regeneron Pharmaceuticals,. Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis. www.prnewswire.com. [2019-01-11]. （原始内容存档于2020-12-04）.
regeneron.com
newsroom.regeneron.com
- Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients (NASDAQ:REGN). newsroom.regeneron.com. [2019-01-11]. （原始内容存档于2018-05-22）.
web.archive.org
- Regeneron Pharmaceuticals. Fortune. [2018-12-31]. （原始内容存档于2019-06-09）.
- Herper, Matthew. How Two Guys From Queens Are Changing Drug Discovery. Forbes (United States). August 14, 2013 [March 22, 2014]. （原始内容存档于2014-03-16）.
- Regulators Approve a Drug for an Eye Condition. The New York Times. Associated Press. November 18, 2011 [2019-01-11]. （原始内容存档于2019-06-05）.
- Archived copy. [2015-07-29]. （原始内容存档于2015-07-27）.
- Inc., Regeneron Pharmaceuticals,. Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis. www.prnewswire.com. [2019-01-11]. （原始内容存档于2020-12-04）.
- Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients (NASDAQ:REGN). newsroom.regeneron.com. [2019-01-11]. （原始内容存档于2018-05-22）.
- FDA approves first treatment for advanced form of the second most common skin cancer (NASDAQ:REGN). fda.gov/NewsEvents. [2019-01-11]. （原始内容存档于2019-04-23）.